212 related articles for article (PubMed ID: 14513437)
1. Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer.
Dowsett M
Semin Oncol; 2003 Aug; 30(4 Suppl 14):58-69. PubMed ID: 14513437
[TBL] [Abstract][Full Text] [Related]
2. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
Santen RJ
J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
[TBL] [Abstract][Full Text] [Related]
3. Challenges in the endocrine management of breast cancer.
Mouridsen HT; Rose C; Brodie AH; Smith IE
Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
[TBL] [Abstract][Full Text] [Related]
4. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
Perez EA
Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
[TBL] [Abstract][Full Text] [Related]
5. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
6. Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer.
Reinhorn D; Yerushalmi R; Moore A; Desnoyers A; Saleh RR; Amir E; Goldvaser H
Breast Cancer Res Treat; 2020 Jul; 182(2):259-266. PubMed ID: 32488391
[TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
Conte P; Frassoldati A
Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
[TBL] [Abstract][Full Text] [Related]
8. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
9. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
10. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor effects of letrozole.
Miller WR; Anderson TJ; Dixon JM
Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
[TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter.
Gandhi S; Verma S
Breast Cancer Res Treat; 2007 Nov; 106(1):1-9. PubMed ID: 17211535
[TBL] [Abstract][Full Text] [Related]
13. Vascular effects of aromatase inhibitors: data from clinical trials.
Howell A; Cuzick J
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):143-9. PubMed ID: 15936188
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors: a safety comparison.
Jonat W; Hilpert F; Kaufmann M
Expert Opin Drug Saf; 2007 Mar; 6(2):165-74. PubMed ID: 17367262
[TBL] [Abstract][Full Text] [Related]
15. Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer.
Yamamoto Y; Iwase H
Int J Clin Oncol; 2008 Oct; 13(5):384-94. PubMed ID: 18946748
[TBL] [Abstract][Full Text] [Related]
16. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
[TBL] [Abstract][Full Text] [Related]
17. Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
Ingle JN
Breast; 2013 Aug; 22 Suppl 2():S180-3. PubMed ID: 24074784
[TBL] [Abstract][Full Text] [Related]
18. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
Howell A; Howell SJ; Clarke R; Anderson E
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular safety profiles of aromatase inhibitors : a comparative review.
Nabholtz JM; Gligorov J
Drug Saf; 2006; 29(9):785-801. PubMed ID: 16944964
[TBL] [Abstract][Full Text] [Related]
20. Role of aromatase inhibitors in the treatment of breast cancer.
Choueiri TK; Alemany CA; Abou-Jawde RM; Budd GT
Clin Ther; 2004 Aug; 26(8):1199-214. PubMed ID: 15476902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]